The usage of drug eluted stents is intended for narrowed coronary vessels of patients with Coronary Artery Diseases (CAD). They developed to minimize the risk of restenosis by the local delivery of antiproliferative drugs, integrated with various polymers to optimize drug kinetics. At the first generation of DES, the total scaffold structure, entry profile, strut width, interaction with the durable polymer coatings, led to poor improvement of the mortality following Percutaneous Coronary Intervention (PCI). These results were relevant to the limited biocompatibility of the polymers and the strong vessel response to the bulky metal structure of these early phase DES struts [1]. The second generation of stents showed more favorable results and better clinical outcomes based on the biodegradable polymers and thinner metallic structures. The current third generation DES, with very thin strut structure and biodegradable polymers shown improved deliverability in tortuous and challenging anatomies and overall better clinical/technical performance. Particularly the combination of resistible in temperature biodegradable polymers (PLGA) and very thin strut structure was manufactured to inhibit the inflammation and also the favorable less vessel wall response due to the favorable metal/tissue ratio. Therefore, we accessed in all comer patient population the safety, efficacy and overall clinical – technical performance of LimusTrack biodegradable polymer Sirolimus eluting very thin strut stent.

Study Design: Data obtain from a single center cohort of patients who have received LimusTrack stent as a part of treatment for coronary artery disease, between May 2025 and August 2026. These patients were identified out of the hospital database and collected for analysis. There were no exclusion criteria but only the lost ones in follow-up.

Description of Device
The LimusTrack is an ultrathin cobalt- chromium platform with a strut thickness of 65 μm and a biodegradable polymer-based coating. In LimusTrack a biodegradable polymer Poly Lactic-co-Glycolic Acid (PLGA) is used to achieve a controlled drug release using a validated formulation of sirolimus (1.40 μm/mm2) timed to elute in 90 – 120 days in parallel; with the polymer resorption. The configuration of the coating is asymmetrical and thicker on the abluminal side than on the luminal side (5 μm vs. 3 μm, respectively), which results in a higher drug dose on the abluminal side of the DES. The LimusTrack is available in sizes ranging from 8 to 48 mm length and from 2.25 to 4.00 mm diameter.

Study procedure and data collection
This was an all-comer study, and the indications for the angioplasty procedure and technique of stent implantation were as per the discretion of the treating physician. All patients were advised to receive dual antiplatelet therapy with clopidogrel and aspirin. Patients who were not pretreated received a bolus dose of 300-600 mg of clopidogrel or 60 mg of prasugrel and ≥ 100 mg of soluble aspirin just before the procedure.

Data was sourced from clinical notes, including in-patient progress notes and out-patient notes and letters, angiogram reports, and procedural angiographic images. Case report forms were completed for all patients, and completely anonymized data were stored in a secure, off-site database. Follow-up data were collected using telephonic interactions by using structured questionnaires developed for this study to determine endpoint status.

Endpoint definitions
The primary endpoint of the study was to determine the rate of Target Lesion Failure, which is defined as the aggregate of cardiac death, target vessel Q-wave or no Q-wave Myocardial Infarction (MI), and TLR procedure during the follow-up period after the index procedure. Secondary endpoint was MACE which is defined as the aggregate of all-cause mortality, any MI and any repeat revascularization (including all target and non-target vessel). The Stent Thrombosis (ST) was classified according to the definitions of the Academic Research Consortium [2]. Procedural success was defined as successful stent placement at the desired position with <30% residual stenosis.

Statistical analysis
Categorical data were presented as counts and percentages. Continuous variables were recorded as mean ± standard deviation. All data were processed using Statistical Package^® SPSS 22.0 for Windows^® (SPSS, Chicago, IL, USA).

Baseline Demographics and clinical characteristics
In total 105 patients with 105 lesions were retrospectively analyzed. Baseline demographics and clinical characteristics are summarized in Table 1. Mean age of patients was 61,33 9.72 years, 73% of them were men and 27% were women. The most common comorbid conditions were diabetes mellitus 43%, smoking, 7%, hypertension 63% and hyperlipidemia 37%. 28% of patients presented ST/No ST elevation myocardial infarction and 33% Unstable angina.

Table 1: Baseline Clinical Characteristics.